Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae

Journal of Clinical Microbiology

Volumn 51, Issue 6, 2013, Pages 1798-1802

  Dallas, Steven D ^a,b   McGee, Lesley ^c   Limbago, Brandi ^d   Patel, Jean B ^e   McElmeel, M Leticia ^b   Fulcher, Letitia C ^b   Lonsway, David R ^d   Jorgensen, James H ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DISK DIFFUSION; DISK DIFFUSION BREAKPOINT; DRUG POTENCY; GENE IDENTIFICATION; GENETIC RESISTANCE; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STREPTOCOCCUS PNEUMONIAE; TETM GENE;

ANTI-BACTERIAL AGENTS; DOXYCYCLINE; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 84878492596     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00125-13     Document Type: Article

References (12)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl 2):S27-S72. doi:10.1086/511159. (Pubitemid 46290553)
2. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement, M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Christianson J, Andes D, Craig WA. 2001. Characterization of the pharmacodynamics of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model, abstr A-1103. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother.
4. Olsvik B, Olsen I, Tenover FC. 1995. Detection of tet(M) and tet(O) using polymerase chain reaction in bacteria isolated from patients with periodontal disease. Oral Microbiol. Immunol. 10:87-92.
5. Christianson J, Andes D, Craig WA. 2001. Magnitude of the 24-H AUC/MIC required for efficacy of doxycycline (DOXY) against Streptococcus pneumoniae (SP) in a murine thigh-infection model, abstr 475. Abstr. 39th Annu. Meet. Infect. Dis. Soc. Am.
6. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed, M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests; approved standard - 10th ed, M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Brunden MN, Zurenko GE, Kapik B. 1992. Modification of the error-bounded classification scheme for use with two MIC breakpoints. Diagn. Microbiol. Infect. Dis. 15:135-140.
9. Metzler DM, DeHaan RM. 1974. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J. Infect. Dis. 130:588-594.
10. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing interpretive criteria and quality control parameters. Approved guideline, 3rd ed, M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing. Twenty-third informational supplement, M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. 18 January 2013. Background and rationale for revised Clinical and Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin. Infect. Dis. [Epub ahead of print.] doi:10.1093/cid/cit017.